

PIKfyve, expressed by CD11c-positive cells, controls tumor immunity



Open Access This file is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. In the cases where the authors are anonymous, such as is the case for the reports of anonymous peer reviewers, author attribution should be to 'Anonymous Referee' followed by a clear attribution to the source work. The images or other third party material in this file are included in the article's Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit <http://creativecommons.org/licenses/by/4.0/>.

Editorial Note: This manuscript has been previously reviewed at another. This document only contains reviewer comments and rebuttal letters for versions considered at *Nature Communications*.

REVIEWERS' COMMENTS

Reviewer #1 (Remarks to the Author):

The authors have provided compelling new data that addresses the questions raised in the last review. I have no further concerns and thank the authors for taking the time to address these aspects.

Reviewer #2 (Remarks to the Author):

The authors made significant efforts to address the comments of the reviewer on the original manuscript.

The authors show data suggesting that PYKfive affects DC activation in the tumor context (new data in Fig. 4) and how the genetic and pharmacological inhibition increases immunity against cancer. They also explored the potential effect in T cell priming and a potential link to NFkB activation.

The minor remaining issue in supp Fig. 1f is addressed.

REVIEWERS' COMMENTS

Reviewer #1 (Remarks to the Author):

The authors have provided compelling new data that addresses the questions raised in the last review. I have no further concerns and thank the authors for taking the time to address these aspects.

Reviewer #2 (Remarks to the Author):

The authors made significant efforts to address the comments of the reviewer on the original manuscript.

The authors show data suggesting that PYKfive affects DC activation in the tumor context (new data in Fig. 4) and how the genetic and pharmacological inhibition increases immunity against cancer. They also explored the potential effect in T cell priming and a potential link to NFkB activation.

The minor remaining issue in supp Fig. 1f is addressed.

AUTHOR RESPONSE

We thank the reviewers for their thoughtful and instructive comments that have significantly improved this manuscript. We appreciate their acknowledgement of our efforts to enhance this work and provide a meaningful contribution to the Nature Communications readership.